( HAWTHORNE N.Y.--(BUSINESS WIRE)--Apr 2...)Acorda Therapeutics to Host Analyst and Investor Reception,Health

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and investor reception on May 2, 2007. This reception will follow a presentation of this data at the American Academy of Neurology (AAN) annual meeting.

Dr. Krupp's presentation will begin at 7:00 pm Eastern Time (ET) and will be able via a live webcast at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c= 194451&eventID=1529938

Archived versions of the webcast will be available for 90 days on our website at http://phx.corporate-ir.net/phoenix.zhtml?c= 194451&p=irol-irhome. (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove extra spaces if they exist.)

The platform presentation of the Phase 3 clinical trial of Fampridine-SR data at the AAN meeting will take place on May 2, 2007 at 4:15 pm ET. This abstract was selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. This presentation was also selected for a second highlights session, Multiple Sclerosis Scientific Topic Highlights, to be presented on May 3, 2007 at 7:00 pm ET. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause act
'"/>

Page: 1 2
Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23